Table 3.
Propensity-score matched cohort.
| Total (%) N = 132 |
TKI plus bevacizumab (%) N = 43 |
TKI alone (%) N = 89 |
p value | |
|---|---|---|---|---|
| Age (mean ± SD) | 60.4 ± 9.8 | 62.4 ± 10.6 | 0.284 | |
| Age ≥ 65 | 54 (40.9) | 15 (34.9) | 39 (43.8) | 0.351 |
| ECOG PS 0–1 | 113 (85.6) | 38 (88.4) | 75 (84.3) | 0.606 |
| Gender | ||||
| Male | 49 (37.1) | 14 (32.6) | 35 (39.3) | 0.565 |
| Current/ex-smoker | 37 (28.0) | 11 (25.6) | 26 (29.2) | 0.836 |
| Histology | ||||
| Adenocarcinoma | 132 (100.0) | 43 (100.0) | 89 (100.0) | 1.000 |
| EGFR mutation | ||||
| L858R | 77 (58.3) | 23 (53.5) | 54 (60.7) | 0.456 |
| 19deletion | 55 (41.7) | 20 (46.5) | 35 (39.3) | |
| Disease stage | ||||
| III | 1 (0.8) | 1 (2.3) | 0 | 0.326 |
| IV | 131 (99.2) | 42 (97.7) | 89 (100.0) | |
| Site of metastasis | ||||
| Brain | 77 (58.3) | 24 (55.8) | 53 (59.6) | 0.710 |
| Liver | 24 (18.2) | 7 (16.3) | 17 (19.1) | 0.812 |
| EGFR TKI administered | ||||
| Gefitinib | 13 (9.8) | 4 (9.3) | 9 (10.1) | 1.000 |
| Erlotinib | 119 (90.2) | 39 (90.7) | 80 (89.9) | |
| Local treatment of brain metastasis | ||||
| WBRT | 38 (28.8) | 10 (23.3) | 28 (31.5) | 0.325 |
| SRS | 1 (0.8) | 1 (2.3) | 0 | |
| Surgical resection | 9 (6.8) | 4 (9.3) | 5 (5.6) | |
WBRT whole brain radiotherapy, SRS stereotactic radiosurgery.